Previous 10 | Next 10 |
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 PR Newswire DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial result...
2024-02-13 20:45:43 ET Summary Baupost Group's 13F portfolio value decreased from $5.21B to $4.59B this quarter. The portfolio is heavily concentrated with Liberty Global, Liberty SiriusXM, Viasat, Alphabet, and Fidelity National Information Services accounting for ~62% of the hol...
2024-01-16 08:19:18 ET Orbicular Pharmaceutical Technologies has agreed to resolve its patent fight with Theravance Biopharma ( NASDAQ: TBPH ) and Viatris ( NASDAQ: VTRS ) unit, Mylan, over the respiratory disorder therapy Yupelri. Per the terms of the agreement, Orbicul...
2024-01-05 06:54:29 ET More on Theravance Biopharma Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript Theravance Biopharma signs cooperation agreement with Irenic Capital Theravance Biopharma Q3 2023 Earnings Preview Seeking Alpha’s Qu...
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) PR Newswire DUBLIN , Jan. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) toda...
2023-12-27 18:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-24 13:08:45 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it’s time to address this...
2023-12-21 17:12:58 ET More on Theravance Biopharma Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript Theravance Biopharma Q3 2023 Earnings Preview Theravance, Mylan settle patent litigation over COPD drug Yupelri Seeking Alpha’s Quant...
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors PR Newswire Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and Maximize Shareholder Value ...
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference PR Newswire DUBLIN , Dec. 18, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced ...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 PR Newswire DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update af...